Shots:
Kiniksa to receive $100M up front & near-term fees and is eligible to receive ~$600M in clinical, regulatory & sales-based milestones alongK with royalties & is currently planning to expand ARCALYST cardiovascular franchise
Genentech to get the rights to develop & commercialize vixarelimab & will focus on the development of vixarelimab, a human mAb targeting OSMRβ in fibrosis where OSM-mediated pathogenesis is used for the intervention in multiple fibrotic indications
The patient enrolment has been completed for the P-IIb clinical trial of vixarelimab in prurigo nodularis. Kiniksa plans to complete the trial but will stop disclosing information in H2’22
Ref: GlobeNewswire | Image: Kiniksa
